Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer
cells. Histamine dihydrochloride may prolong survival and improve quality of life in patients
with metastatic kidney cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-2 with or
without histamine dihydrochloride in treating patients who have metastatic kidney cancer.